Activin Receptor Inhibitors—Dalantercept

BMP9 Mutations Cause a Vascular-Anomaly Syndrome with Phenotypic Overlap with Hereditary Hemorrhagic Telangiectasia

(2013) Whitney L. Wooderchak-Donahue et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor-like Kinase-1 Ligand Trap, in Patients with Advanced Cancer

(2013) J. C. Bendell et al.   CLINICAL CANCER RESEARCH

Context-dependent signaling defines roles of BMP9 and BMP10 in embryonic and postnatal development

(2013) H. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer

(2012) L. S. Rosen et al.   CLINICAL CANCER RESEARCH

Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies

(2011) Dana D. Hu-Lowe et al.   CANCER RESEARCH

Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis

(2010) Sara I. Cunha et al.   JOURNAL OF EXPERIMENTAL MEDICINE

ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth

(2010) D. Mitchell et al.   MOLECULAR CANCER THERAPEUTICS

ALK1 signaling regulates early postnatal lymphatic vessel development

(2009) K. Niessen et al.   BLOOD

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE